LOUISVILLE, CO -- (MARKET WIRE) -- October 30, 2006 -- GlobeImmune, Inc. today announced positive interim results from Study GI-5005-01, a randomized, placebo-controlled, multi-center, dose-escalation, Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus (HCV). The data were presented today at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). GI-5005 generated cellular immune responses in 12/29 patients (41%), elicited a statistically significant improvement in alanine amino transferase (ALT) levels from baseline and caused near 1 log10 viral load reductions in three patients, two of whom had positive immune responses after only a three month course of GI-5005 monotherapy. No meaningful safety concerns were seen in the study to date.
